Tiziana Life Sciences Reports Positive Expanded Access Data for Intranasal Foralumab in Progressive MS
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On May 19, 2026, Tiziana Life Sciences reported updated clinical data from March 2025 through March 2026 from its Expanded Access program testing intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis. The company said the fully human anti-CD3 antibody remained extremely well tolerated over extended treatment, with trends toward stabilization of disability and clinically meaningful fatigue improvements in most participants, though the small sample size means results are not yet statistically significant.
Investigators highlighted a favorable trend in reduced confirmed disability progression on the Expanded Disability Status Scale and noted that 64% of patients achieved at least a four-point improvement on the Modified Fatigue Impact Scale. The latest findings reinforce Tiziana’s positioning of intranasal foralumab as a potential new treatment paradigm for progressive forms of multiple sclerosis, where approved options are limited, and support the rationale for advancing ongoing controlled trials that could influence future regulatory and commercial prospects if outcomes are confirmed.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough immunotherapies using alternative drug delivery technologies, particularly intranasal administration. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody aimed at treating neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis, with a pipeline supported by patented delivery platforms.
Average Trading Volume: 150,731
Technical Sentiment Signal: Buy
Current Market Cap: $162.8M
For detailed information about TLSA stock, go to TipRanks’ Stock Analysis page.
